ArticleNature communications2026
A dual context-aware basecaller for nanopore direct RNA sequencing.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nanopore direct RNA sequencing and the epitranscriptome: Advances in mapping native RNA landscapes.iMeta · 2026Review
- A dual context-aware basecaller for nanopore direct RNA sequencing.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Nanopore direct RNA sequencing (DRS) offers distinct advantages for transcriptome analysis over the traditional high-throughput RNA sequencing methods by preserving native RNA modifications, eliminating polymerase chain reaction bias, and simplifying the workflow. However, its high basecalling error rate remains a significant hurdle. Here we introduce Coral, a dual context-aware nanopore DRS basecaller that uses a Transformer-based encoder-decoder architecture to capture contextual dependencies at both the signal and sequence levels, substantially improving accuracy. Coral achieves up to a 6.17% improvement in accuracy on human RNA samples compared to Oxford Nanopore Technologies' Dorado basecaller. This improved accuracy enables the detection of 26% more annotated transcript isoforms. Coral also enhances the downstream haplotype phasing, reducing switch errors by up to 78.8% and Hamming errors by 76%, while phasing 36% more single nucleotide polymorphisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.